Summary. -To test the possible inhibition of hepatitis B virus (HBV) replication and expression by small interfering RNAs (siRNAs) targeting simultaneously covalenthy closed circular DNA (dnacccDNA) and X antigen, corresponding recombinant plasmids were transfected into HepG2.2.15 cells and the levels of cccDNA, HBXAg, HBcAg, and HBeAg were assayed at various times post transfection. As expected, the single siRNAs showed marked inhibitory eff ects but their combination was even more effi cient. Th ese results provide a new insight into the development of a potential anti-HBV strategy of enhancing the effi cacy of individual antivirals and overcoming the high mutation rate of HBV.
Introduction
Hepatitis B virus (HBV) infection is a major health problem with more than 350 million chronic carriers worldwide, who are at high risk for developing liver cirrhosis and hepatocellular carcinoma (Beasley et al., 1981; Lupberger and Hildt, 2007) . Th e mechanisms of HBV pathogenicity remain unclear and molecular-biological studies are required. Although the oral cytosine nucleoside analogue lamivudine (3TC) has been clinically used for the treatment of chronic HBV infection and potently inhibited HBV replication by interfering with HBV reverse transcriptase activity (Doong et al., 1991; Dienstag et al., 1995) , 3TC-resistant HBV strain has been reported in longterm therapy (Li et al., 2007) . Th us, a new potential agent for anti-HBV therapy should be evaluated with special focus on its inhibitory eff ect against the recurrence of HBV infection.
Th e HBV genome is a partially double-stranded circular DNA of 3.2 kb that is transcribed into 3.5-, 2.4-, 2.1-, and 0.7-kb viral transcripts containing four open reading frames (denoted S, C, P, and X). cccDNA serves as the template for viral transcription during HBV replication and its production is regulated and amplifi ed by an intra-cellular pathway, in which newly synthesized genomic DNA is recycled to the nuclei (Tuttleman et al., 1986; Rollier et al., 1999) . However, the elimination of cccDNA in infected hepatocytes remains a challenge in therapy of HBV-infected patients. Th e HBX gene is the smallest HBV gene, coded by 462 nt, and encodes a 17 kDa protein with 154 aa (Fujiyama et al., 1983) . Th is protein is a pleiotropic transactivator, which stimulates HBV promoters and enhancers as well as a wide range of other viral promoters through protein-protein interactions (Spandau et al., 1988; Nakatake et al., 1993; Fiedler et al., 2006) . Since the HBV X protein antigen (HBXAg) is critically implicated in HBV-mediated hepatic cell cancer (HCC) and consistently expressed in all four viral mRNAs, it seems to be an attractive target for anti-HBV siRNA development.
In this study, we constructed plasmids expressing siRNAs that targeted HBV cccDNA and X gene, respectively. We tested their possible antiviral eff ects in HepG2.2.15 cells individually and in combination, assuming that the latter approach would be more effi cient. Th e obtained results on reduction of the levels * Corresponding author. E-mail: denghongx@scu.edu.cn; phone: +86-28-85164063.
a Th e authors contributed equally to this work. Abbreviations: cccDNA = covalently closed circular DNA; HBeAg = hepatitis B e antigen; HBcAg = hepatitis B core antigen; HBsAg = hepatitis B surface antigen; HBV = hepatitis B virus; HBXAg = the HBV X protein antigen; HCC = hepatic cell cancer; IFA = immunofl uorescence assay; RNAi = RNA interference; siRNA = small interfering RNA; 3TC = lamivudine of cccDNA, HBXAg, hepatitis B core antigen (HBcAg), and hepatitis B e antigen (HBeAg) confi rmed this assumption.
Materials and Methods
Plasmid constructs. Briefl y, 19 nt-long inverted cccDNA sequences were cloned into the plasmid pGenesil 2.4, while 19 nt-long inverted HBXAg sequences were cloned into the plasmid pGenesil 2.1. Oligonucleotides used to code the sense strand of siRNA included siRNA-cccDNA (5ʹ-GATCTCAATCTCGGGAATC-3ʹ), siRNA-HBX (5ʹ-GAGGACTCTTGGACTCTCA-3ʹ), siRNA-HBX+ siRNA-cccDNA and control siRNA-HK (5ʹ-GACTTCATAA GGCGCATGC-3ʹ). Th e control sequence HK had no homology to any mammalian sequence. All plasmid constructs were verifi ed by restriction analysis and DNA sequencing.
Cell cultures and transfection. HepG2.2.15, the human hepatoma cell line, was maintained in DMEM with 10% fetal bovine serum in 5% CO 2 humidifi ed air as previously described (Li et al., 2007) . Cells were seeded at a density of 2×10 5 cells per well in 6-well clustered plates. 24 hrs aft er incubation, the cells were transfected with 2 μg siRNA-expressing plasmid using the Lipofectamine 2000 reagent according to the manufacturer΄s instructions (Sells et al., 1987) . One group was treated with 0.5 μmol/l 3TC. Forty-eight, 72, and 96 hrs aft er transfection, culture media were collected and cells were harvested for HBV replication assay. All experiments were performed in triplicate.
Real-time PCR. To measure the viral DNA, DNA was extracted from the transfected cells using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). For quantifi cation of HBV cccDNA by real-time PCR, 250 nmol/l of the probe (5ʹ-TTTTTCAAGCCTCCAAGC TGTGCCTTG-3ʹ) and 900 nmol/l of each PCR primer (F-TGTC TGCGGCGTTTTATCA, R-GGTCCCGTGCTGGTAGTTG) were used. Th e PCR was carried out in 50 μl volume using FTC2000 (Canada). Th e PCR program consisted of an initial denaturing step at 94 o C for 4 min, followed by 35 amplifi cation cycles at 94 o C for 20 sec, 60 o C for 30 sec, and 72 o C for 30 sec. RT-PCR. RNA expression level was determined by semiquantitative RT-PCR analysis. Seventy-two hrs aft er transfection, total RNA was extracted directly from the transfected cells using Trizol reagent. Th e purifi ed total RNA was reversely transcribed with ExScript RT reagent kit (TaKaRa Biotechnology, Dalian, China) following the manufacturer΄s protocol. A RT-PCR experiment targeting GAPDH gene was run as an internal control. Primer sequences specifi c for the HBV X gene were: 5ʹ-T CCCCGTCTGTGCCTTCTC-3ʹ (forward primer), 5ʹ-GTGG TCACCATGCGACGTG-3ʹ (reverse primer). GAPDH primers were: 5ʹ-GTCGGTGTGAACGGATTT-3ʹ (forward primer) and 5ʹ-ACTCCACGACGTACTCAGC-3ʹ (reverse primer). Th e PCR amplifi cation product was analyzed by electrophoresis in 1% agarose gel stained with ethidium bromide.
Western blot analysis. Ninety-six hrs after transfection, HepG2.2.15 cells were lysed with buff er containing 1% Triton X-100, 1% deoxycholate (Jin et al., 2001) . Protein concentrations were determined using the BCA Kit (Th ermo scientifi c, Fremont, CA, USA) and equalized before loading. Aft er centrifugation, 30 μg of total proteins was separated on 15% SDS-polyacrylamide gels, followed by blotting onto the PVDF membrane. Th e blot was blocked with 5% non-fat dried milk, probed with specifi c anti-HBXAg antibodies (Abcom, Cambridge, MA, USA) (Yun et al., 2000; Feng et al., 2010) , and blots were developed with HRPconjugated secondary antibodies and chemiluminiscent substrate on Kodak X-Ray fi lms.
ELISA. To assess the eff ects of RNAi on viral antigen expression, HBeAg and HBsAg levels were measured by ELISA following the manufacturer's instructions (Zhongshan Golden Bridge Biotech, Beijing, P.R. China).
Immunofl uorescence assay (IFA). Ninety-six hrs aft er transfection, HepG2.2.15 cells were fixed with 4 % paraformaldehyde for 10 min and washed three times with TBS. Cells were stained for HBcAg using anti-HBcAg (Zhongshan Golden Bridge Biotech, Beijing, China) antibody overnight at 4°C and then anti-mouse Cy3-conjugated secondary antibody for 1 hr at room temperature. Aft er counterstaining with DAPI, cells were washed with TBS three times and viewed with a fl uorescence microscope (Carl Ziess Microimaging, Jena, Germany).
Results

Th e eff ects of siRNA on HBV cccDNA level
HBV cccDNA is an important parameter for the therapy of chronic HBV infection. To evaluate whether siRNAs with specifi c target can eff ectively inhibit viral cccDNA, we isolated viral cccDNA from cells at 96 hrs post-transfection. Real-time quantitative PCR and the relative standard curve method were used to analyze the results.
Quantitative assay revealed that the HBV cccDNA levels in siRNA-cccDNA, siRNA-HBX, siRNA-HBX + siRNAcccDNA, siRNA-HK and 3TC groups were in the 30.3%, 71.3%, 21.7%, 92.1%, and 59.8%, respectively, of that in control group. Th e greatest inhibitory eff ect was exhibited in the combined therapy group (siRNA-HBX + siRNAcccDNA) (Fig. 1) .
Eff ects of siRNAs on HBXAg, HBsAg, HBeAg, and HBcAg expression
As the precursor of the protein, the mRNA level has been the refl ector, which provides information about the protein level at a certain distance (Xin et al., 2008) . It has been proved that the mRNA level was markedly reduced at 96 hrs post transfection with siRNA (Dykxhoorn et al., 2005) . To assess whether siRNAs specifi cally inhibited HBX mRNA, we used semi-quantitative RT-PCR analysis to determine the levels of HBX mRNA in HepG2.2.15 cells at 96 hrs aft er transfection.
Th e results showed that the levels of HBX mRNA were dramatically reduced in HepG2.2.15 cells aft er the treatment with siRNA and 3TC compared with the treatment of siRNA-HK, while the greatest reduction rate was in the combined therapy group (siRNA-HBX + siRNA-cccDNA) (Fig. 2) .
To test whether specifi c siRNA could inhibit the expression of HBXAg, western blot was performed 96 hrs aft er transfection. Th e GAPDH was used as an internal control.
As shown in Fig. 3 , the level of HBXAg was reduced to diff erent degree in all transfected cells. Th e combined therapy group (Fig. 3) had the greatest decrease of HBXAg, while the protein levels in cells transfected with nonspecifi c siRNA showed nearly no change.
To evaluate the infl uence of RNAi on HBV antigen expression, HepG2.2.15 cells were transfected with HBX or cccDNA siRNA. HBsAg and HBeAg concentrations in the culture media of transfected and control cells were measured at 48, 72, and 96 hrs post transfection by ELISA. Th e HBeAg levels in all cells transfected with siRNA or treated with 3TC were signifi cantly reduced compared to those transfected with an empty vector (Fig. 4b) . Meanwhile, the level of HBsAg was also reduced in both the siRNA-transfected cells and the 3TC-treated cells (Fig. 4a) . For both HBsAg and HBeAg, the combination therapy with siRNAs was more eff ective than any individual therapy.
At 96 hrs post transfection, the expression level of HBcAg in transfected cells was detected by immunofluorescent staining. Th e amount of HBcAg was reduced both in the siRNA-transfected cells and the 3TC-treated cells. Th e cells treated with combined therapy expressed approximately 14.9% HBcAg of control as measured by Image Pro-Express soft ware (Fig. 5) .
Discussion
RNAi is an endogenous cell process that can suppress gene expression in a highly specifi c manner. It is believed to represent an ancestral form of nucleic acid-based elimination of intracellular pathogens. Now it is providing new approaches for the development of therapies for a variety of diseases, including tumors and viral infections (Hamasaki et al., 2003; Chan et al., 2006) . It has been demonstrated that RNAi could attenuate the replication of HBV genome in cell culture (Shlomai et al., 2003) . Th erapeutic interfering RNA can be directly introduced into cells as exogenously produced siRNA or can be synthesized within cells by vector-based systems. Silencing mediated by both strategies has been shown to be highly eff ective (Elbashir et al., 2001; Morrissey et al., 2005) . Recent progress in chemical modifi cation of siRNA has improved both the longevity and specifi city of these agents (Seeger et al., 2000; Jackson et al., 2006; Zimmermann et al., 2006) . Th ese reports have demonstrated that RNAi technology could be used to suppress HBV in cell cultures and animal models, Real-time PCR. Levels of cccDNA in cells exposed to blank (1), siRNA-HK, negative control (2), 3TC (3), siRNA-HBX (4), siRNA-cccDNA (5), siRNA-HBX + siRNA-cccDNA (6).
Fig. 2 Eff ects of siRNAs on HBXAg expression
RT-PCR. Levels of HBX mRNA in cells exposed to blank (1), siRNA-HK, negative control (2), 3TC (3), siRNA-HBX (4), siRNA-cccDNA (5), siRNA-HBX + siRNA-cccDNA (6).
Fig. 3 Eff ects of siRNAs on HBXAg level
Western blot analysis, GAPDH served as an internal control. Levels of HBXAg in cells exposed to blank (1), 3TC (2), siRNA-cccDNA (3), siRNA-HBX (4), siRNA-HBX + siRNA-cccDNA (5), siRNA-HK, negative control (6).
which provides insight into application of this technique in controlling infectious human hepatitis.
During virus replication, cccDNA is considered as the template for DNA transcription and its production is regulated and amplifi ed by an intra-cellular pathway, in which newly synthesized genomic DNA is delivered to the nuclei. Th e HBXAg is a multifunctional factor related to an increasing risk of hepatocellular carcinoma in HBV patients and it is important for the transcriptional regulation of HBV genes (Feitelson et al., 1993; Benn et al., 1994; Wang et al., 1994; Takada et al., 1995) . Apart from transactivation of many promoters, activities linked to HBXAg include stimulation of signal transduction (Sirma et al., 1998) and binding to well-known proteins such as p53 (Takada et al., 1990; Lee et al., 1995) , proteasome subunits (Andrisani et al., 1990) , and UV-damaged DNA-binding protein (Murakami, 2001) . It has been reported that viral mutations could escape single synthetic siRNA treatments (Xin et al., 2008) . In previous work, a therapeutic silencing vector that targeted HBV with four separate pol III-driven siRNA cassettes showed effi cacy in cell culture and animal models of infection (Fu et al., 1998) . Recently, combination therapy has emerged as a new approach in the treatment of chronic HBV infection with the objective to decrease the viral loads. Th us, the treatment with the combination of two targets, HBXAg and cccDNA, can be prospective and eff ective.
To investigate the eff ects of selected siRNA molecules on HBV gene expression and viral replication in vitro, we used HepG2.2.15 (a derivative of the human HepG2 hepatoma cell line), which has been stably transformed with HBV genome and used as an in vitro model for HBV replication (Zhao et al., 2006; Guan et al., 2007) . Th e results of our study indicated that siRNA-cccDNA, siRNA-HBX, siRNA-HBX + siRNA-cccDNA had signifi cant eff ect on HBV cccDNA amplifi cation and the expression of HBXAg in HepG2.2.15 cells, and subsequently blocked the viral protein production and inhibited HBV replication. Th e anti-HBV eff ects of therapeutic siRNA were more eff ective than the treatment with 0.5 μmol/l 3TC in HepG2. 2. 15 cells. More importantly, dual siRNA could simultaneously inhibit the synthesis of cccDNA and HBX gene by 78.3% and 72.5%, respectively. Th erefore, this dual siRNA system could provide a more powerful tool to study the gene function and could be potentially used in the treatment of viral infection.
RNAi used as an anti-HBV tool seems to have some important advantages: First, specifi c target of viral transcripts severely impairs virus replication and promotes its eradication, without activating nonspecifi c cellular responses, which can minimize undesirable side eff ects. Second, the numerous potential targets make it possible to target conserved regions, which can limit the ability of the virus to create escape mutants.
In the last 30 years, HBV infection aff ects millions of people each year worldwide. Current therapies of HBV infection include nucleoside analogs such as 3TC, which has provided some degree of cure, but the effi ciency of treatment is limited due to the virus gene mutation. HBV patients currently have few therapeutic options and new approaches are needed to improve the quality of life. As a potential therapy, RNAi seems to be a promising alternative strategy. In our study, combined treatment targeting both cccDNA and HBX gene strongly inhibited not only HBV replication at the protein and mRNA level, but also the cccDNA transcription activity. Although HBV infection remains a major health problem, our experiments provide a new insight into the anti-HBV strategy, enhancing the anti-HBV effi cacy and overcoming the high mutation rate of HBV. Eff ects of siRNAs on HBcAg level IFA. Levels of HBeAg in cells exposed to blank, siRNA-HK (negative control), 3TC, siRNA-HBX, siRNA-cccDNA, and siRNA-HBX + siRNA-cccDNA.
